Ken Griffin Midatech Pharma PLC Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$0.83 - $1.26 $34,391 - $52,208	-41,435 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$1.05 - $1.85 $43,506 - $76,654	41,435 New	41,435 $43,000
Q3 2021 Nov 15, 2021	SELL	$1.68 - $2.19 $43,211 - $56,328	-25,721 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$1.78 - $2.95 $205,390 - $340,394	-115,388 Reduced 81.77%	25,721 $53,000
Q1 2021 May 17, 2021	BUY	$1.92 - $3.8 $238,168 - $471,374	124,046 Added 726.99%	141,109 $301,000
Q4 2020 Feb 16, 2021	BUY	$1.77 - $2.36 $30,201 - $40,268	17,063 New	17,063 $32,000

Ticker MTP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 3,939,740
Market Cap $512K
Description
Midatech Pharma plc, a drug delivery technology company, focuses on the research and development of medicines in the United Kingdom, rest of Europe, and internationally. The company is developing MTX110, a direct delivery treatment for diffuse intrinsic pontine glioma, medulloblastomas, and glioblastoma multiforme; MTX114, an immuno-suppressant ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.